Precision cancer company Syapse is teaming with Seoul National University Hospital and Asian AWS partner Megazone
Foundation Medicine will provide genomic profiling for the EORTC's Screening Patients for Efficient Clinical Trial Access program.
UCSF researchers will use NantHealth's GPS Cancer molecular analysis test in their molecular profiling study of metastatic breast cancer.
The agency said that its action on MSK IMPACT "advances a policy framework that paves the way for the efficient review and availability of other NGS-based cancer profiling tools."
The Irving, Texas-based company claims that three of Foundation Medicine's cancer molecular profiling tests infringe five of its US patents.
Publishing house Hearst is pushing into precision medicine with a $75 million investment in M2Gen, the informatics subsidiary of Moffitt Cancer Center.
An international research team profiled more than 7,500 tumor genomes, including small-bowel adenocarcinoma, colorectal cancer, and gastric cancer genomes.
At the AACR annual meeting, researchers presented results from the Phase II SUMMIT trial investigating the pan-HER-targeted therapy neratinib.
Caris will be on the lookout for pancreatic cancer patients with low DNA mismatch repair protein expression.
Lunatus will have exclusive rights to distribute GPS Cancer to physicians in the UAE, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.